Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
ZyVersa Therapeutics, Inc. (ZVSA) had Stock-Based Compensation of $0.21M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-19.81M |
|
-- |
|
-- |
|
$20.75M |
|
$-20.75M |
|
$0.09M |
|
$-20.66M |
|
$-20.66M |
|
$-19.81M |
|
$-19.81M |
|
$-19.81M |
|
$-19.81M |
|
$-20.75M |
|
$-20.75M |
|
7.74M |
|
7.74M |
|
$-2.56 |
|
$-2.56 |
|
| Balance Sheet Financials | |
$1.00M |
|
-- |
|
$0.04M |
|
$1.04M |
|
$12.77M |
|
-- |
|
-- |
|
$12.77M |
|
$-11.73M |
|
$-11.73M |
|
$-11.73M |
|
8.10M |
|
| Cash Flow Statement Financials | |
$-4.70M |
|
-- |
|
$3.70M |
|
$1.53M |
|
$0.53M |
|
$-1.00M |
|
|
Stock-Based Compensation |
$0.21M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
168.91% |
|
168.91% |
|
-1903.90% |
|
168.91% |
|
$-1.45 |
|
$-0.61 |
|
$-0.61 |
|